Targeted therapy approaches for mCRC continue to evolve as new data helps define how to best improve outcomes. Decisions regarding treatment for patients with mCRC require that clinicians be familiar with existing and new targeted therapies as well as the most effective and tolerable combination regimens.

The promising pCR data for total neoadjuvant therapy and dostarlimab and the impact these treatment strategies may have for the watch-and-wait approach have exciting implications for patients who are not candidates for surgery or for those who wish to avoid surgical morbidity.

Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy among the approaches of recent interest. Clinicians can benefit from education on relevant clinical trial results related to trimodal therapy for localized rectal cancer and guidance on how these data may be best applied to clinical practice.

The determination of an optimal treatment plan for patients with rectal cancer is a complex process that is reliant on balancing the potential risks and benefits of each treatment option based on an individual patient’s characteristics. Clinicians must be educated about on emerging approaches to personalized treatment for patients with rectal cancer so that the most appropriate treatment options can be offered to each patient.

Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define the approaches that will best improve outcomes while reducing adverse effects, as well as which patients will benefit from these treatment methods.  Clinicians would benefit from education on relevant clinical trial results and how they may be best applied to clinical practice.